Reply to effect of CYP2C19*2 and *3 on clinical outcome in ischemic stroke patients treated with Clopidogrel.
Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA. Electronic address: dimmoris@yahoo.com.
Demetrios
D
Moris
1st Department of Surgery, Laikon General Hospital, University of Athens, Athens, Greece.
Chris
C
Bakoyiannis
1st Department of Surgery, Laikon General Hospital, University of Athens, Athens, Greece.
Georgios
G
Karaolanis
1st Department of Surgery, Laikon General Hospital, University of Athens, Athens, Greece.
Sotirios
S
Georgopoulos
D002545:Brain Ischemia / Q000150:complications; D000077144:Clopidogrel; D065731:Cytochrome P-450 CYP2C19 / Q000235:genetics*; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D020521:Stroke / Q000188:drug therapy* / Q000209:etiology; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000627:therapeutic use
D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D013988:Ticlopidine